Friday, 30 September 2022


Daiichi Sankyo to build biopharmaceuticals facility for govt

13 July 2012 | News | By BioSpectrum Bureau

Daiichi Sankyo to build biopharmaceuticals facility for govt

Daiichi Sankyo is planning an investment of over $36 million

Daiichi Sankyo is planning an investment of over $36 million

Singapore: Daiichi Sankyo has been approved for the Japanese Ministry of Economy, Trade and Industry's production facility building grant, which is part of the Ministry's second production facility building initiative. Daiichi Sankyo will apply the grant toward the expansion of production facilities for biopharmaceuticals.

Daiichi Sankyo is planning an investment of over $36 million (2.9 billion yen) to expand clinical trial and initial commercialization production facilities for biopharmaceuticals at the Tatebayashi Biopharmaceuticals Center (located in Chiyoda-cho, Gunma Prefecture). The grant from the Japanese government to be received by Daiichi Sankyo will cover a portion of the construction cost of the new production facilities.

In order to fully support this national production facility building initiative, Daiichi Sankyo will strengthen the internal production platform for biopharmaceuticals, including antibody drugs, leading directly to the introduction of biopharmaceutical and biosimilar therapies in the future and promoting the further evolution of the hybrid business model.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account